A Phase I Open-label Pharmacokinetics And Safety Study Of Talazoparib (mdv3800) In Patients With Advanced Solid Tumors And Normal Or Varying Degrees Of Renal Impairment
Phase of Trial: Phase I
Latest Information Update: 24 Nov 2017
At a glance
- Drugs Talazoparib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Pfizer
- 20 Nov 2017 Planned End Date changed from 19 Dec 2017 to 19 Feb 2018.
- 20 Nov 2017 Planned primary completion date changed from 19 Dec 2017 to 19 Feb 2018.
- 27 Jul 2017 Status changed from not yet recruiting to recruiting.